English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Ceftolozane-tazobactam (TOL-TAZ) is a novel cephalosporin combination that is beneficial for the treatment of multidrug-resistant (MDR) Pseudomonas infections. However, little data are available on the utility of TOL-TAZ for patients with bloodstream infections (BSIs) caused by this organism. Methods A retrospective, multicenter chart review was conducted at 11 hospitals to evaluate the utility of TOL-TAZ for MDR Pseudomonas BSIs from June 2016 to February 2018. Patients were included if they were over 18 years old with positive blood cultures for Pseudomonas aeruginosa and received TOL-TAZ for at least 24 hours. Patients were evaluated for in-hospital and 30-day mortality, as well as microbiologic and clinical cure. Results Characteristic Results (N = 25) Male gender, n (%) 15 (60) Age, median (range) 60 (52–66) Charlson comorbidity index, median (IQR) 5 (4–7) APACHE II score, median (IQR) 19 (16.25–25.5) ICU, n (%) 15 (60) Organ transplant, n (%) 8 (32) Concomitant antibiotics used, n (%) 14 (56) Aminoglycoside, n/N (%) 8/14 (57) Fluoroquinolone, n/N (%) 5/14 (35) Polymyxin, n/N (%) 2/14 (14) β-Lactam, n/N (%) 1/14 (7) Duration of TOL-TAZ, days (median, IQR) 13 (8-14) Susceptibility to TOL-TAZ, n/N tested (%) 19/20 (95) High dose (3g every 8 hours), n (%) 6 (24) Renal dose adjustment, n (%) 8 (32) Adverse events, n (%) 1 (4) Primary infection 30 day mortality, n/N (%) In-hospital mortality, n/N (%) Microbiologic success, n/N (%) Clinical Success, n/N (%) Primary bacteremia 1/7 (14.3) 0/7 (0) 7/7 (100) 6/7 (85.7) Pneumonia 5/8 (62.5) 5/8 (62.5 3/8 (37.5) 3/8 (37.5) UTI 1/6 (16.7) 1/6 (16.7) 6/6 (100) 6/6 (100) Intra-abdominal 0/4 (0) 0/4 (0) 4/4 (100) 4/4 (100) 30 day mortality, n (%) 7 (28) In hospital mortality, n (%) 6 (24) Microbiologic cure, n (%) 20 (80) Clinical success, n (%) 19 (76) Conclusion In this multi-center evaluation of 25 patients from 11 health centers, mortality was seen at 30 days and at the end of stay in 28% and 24% of patients, respectively. Clinical and microbiologic success occurred in over 70% of patients. One patient developed C. difficile infection. The 7 patients with primary bacteremia had microbiologic success and survived their hospital stay. Two of 3 patients with pneumonia who survived received high dose TOL-TAZ. TOL-TAZ is an option for patients with MDR Pseudomonas bloodstream infections. Disclosures J. Gallagher, Achaogen: Consultant, Consulting fee. Merck: Consultant, Grant Investigator and Speaker’s Bureau, Consulting fee and Research grant. Allergan: Consultant and Speaker’s Bureau, Consulting fee. Astellas: Consultant and Speaker’s Bureau, Consulting fee. Cempra: Consultant, Consulting fee. Cidara: Consultant, Consulting fee. CutisPharma: Consultant, Consulting fee. Paratek: Consultant, Consulting fee. Shionogi: Consultant, Consulting fee. Tetraphase: Consultant, Consulting fee. Theravance: Consultant, Consulting fee. The Medicines Company: Consultant, Consulting fee. Melinta: Speaker’s Bureau, Consulting fee.

open forum infectious diseases

2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i> Bloodstream Infections: A Multi-Center Study

2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study